Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P25024

UPID:
CXCR1_HUMAN

ALTERNATIVE NAMES:
CDw128a; High affinity interleukin-8 receptor A; IL-8 receptor type 1

ALTERNATIVE UPACC:
P25024; B2R6Q3; Q2YEF8; Q2YEG4; Q2YEG5; Q2YEG7; Q2YEG8; Q53R18; Q6IN95; Q8N6T6; Q9P2T8; Q9P2T9; Q9P2U0; Q9P2U1; Q9P2U2

BACKGROUND:
The C-X-C chemokine receptor type 1, with alternative names such as CDw128a, High affinity interleukin-8 receptor A, and IL-8 receptor type 1, is integral to the immune system's response to inflammation. It binds to IL-8, leading to the activation of neutrophils through a G-protein mediated phosphatidylinositol-calcium second messenger system. This receptor's function underscores its importance in the body's defense mechanism against infections and in the regulation of inflammatory processes.

THERAPEUTIC SIGNIFICANCE:
The exploration of C-X-C chemokine receptor type 1's function offers a promising pathway for the development of new therapeutic strategies. Given its crucial role in neutrophil activation and the inflammatory response, targeting this receptor could lead to innovative treatments for controlling excessive inflammation, thereby providing significant benefits in the management of inflammatory and autoimmune diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.